The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis

Douglas Tremblay, Lara Cavalli, Oumar Sy, Shelonitda Rose, John Mascarenhas

Research output: Contribution to journalEditorial

1 Scopus citations
Original languageEnglish
Pages (from-to)e463-e466
JournalClinical Lymphoma, Myeloma and Leukemia
Volume22
Issue number7
DOIs
StatePublished - Jul 2022

Keywords

  • JAKARTA
  • JAKARTA2
  • Metabolic effects
  • Ruxolitinib
  • Weight gain

Cite this